The Hindu Business Line : Ranbaxy gets nod for Lisinopril

Ranbaxy Laboratories has announced that it has received approval to manufacture and market Ran- Lisinopril 5, 10 and 20 mg tablets from Health Canada, Therapeutic Products Directorate (TPD). “Lisinopril is indicated for the treatment of hypertension and may be used alone as initial therapy or concomitantly with other classes of antihypertensive agents. It can also be used as adjunctive therapy in the management of heart failure in patients who are not responding adequately to diuretics and digitalis, as well as in the treatment of hemodynamically stable patients within 24 hours of acute myocardial infarction, to improve survival,” the company said in a release issued on Monday.

According to estimates, the total market for Lisinopril 5, 10, and 20 mg oral tablets in Canada is C$46 million. “We are pleased to receive this approval for Ran- Lisinopril to expand Ranbaxy’s product portfolio of accessible generic product offerings. It will be manufactured in Ranbaxy’s cGMP facility located in North Brunswick, New Jersey,” Mr Paul Drake, President, Ranbaxy Pharmaceuticals-Canada Inc, said in the release. —

Our Bureau

More Stories on : Announcements | Pharmaceuticals | Ranbaxy Laboratories Ltd

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page